These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 21826070)

  • 1. Interventional cardiology: Antithrombotic drug and stent choices in primary PCI.
    Menees DS; Bates ER
    Nat Rev Cardiol; 2011 Aug; 8(9):483-4. PubMed ID: 21826070
    [No Abstract]   [Full Text] [Related]  

  • 2. Complete resolution of very late stent thrombosis with systemic thrombolysis.
    Yiginer O; Kardesoglu E; Ozmen N; Aparci M; Cebeci BS
    J Cardiovasc Med (Hagerstown); 2011 Oct; 12(10):765-7. PubMed ID: 20671569
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.
    Saltzman AJ; Stone GW; Claessen BE; Narula A; Leon-Reyes S; Weisz G; Brodie B; Witzenbichler B; Guagliumi G; Kornowski R; Dudek D; Metzger DC; Lansky AJ; Nikolsky E; Dangas GD; Mehran R
    JACC Cardiovasc Interv; 2011 Sep; 4(9):1011-9. PubMed ID: 21939942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial.
    Di Lorenzo E; De Luca G; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G
    JACC Cardiovasc Interv; 2009 Jun; 2(6):515-23. PubMed ID: 19539255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice?
    Brodie BR
    Catheter Cardiovasc Interv; 2008 May; 71(6):816-21. PubMed ID: 18412079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of drug-eluting stents in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a meta-analysis of randomised trials and an adjusted indirect comparison.
    Piscione F; Piccolo R; Cassese S; Galasso G; De Rosa R; D'Andrea C; Chiariello M
    EuroIntervention; 2010 Feb; 5(7):853-60. PubMed ID: 20142203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
    JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The lack of endothelization after drug-eluting stent implantation as a cause of fatal late stent thrombosis.
    Jakabcin J; Bystron M; Spacek R; Veselka J; Kvasnak M; Kala P; Malý J; Cervinka P
    J Thromb Thrombolysis; 2008 Oct; 26(2):154-8. PubMed ID: 17764000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of drug-eluting stents placed in the setting of ST-segment elevation myocardial infarction.
    Ziada KM; Charnigo R; Moliterno DJ
    JACC Cardiovasc Interv; 2011 Jan; 4(1):39-41. PubMed ID: 21251627
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study.
    Wijnbergen I; Helmes H; Tijssen J; Brueren G; Peels K; van Dantzig JM; Van' t Veer M; Koolen JJ; Pijls NH; Michels R
    JACC Cardiovasc Interv; 2012 Mar; 5(3):313-22. PubMed ID: 22440498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial.
    Vink MA; Dirksen MT; Suttorp MJ; Tijssen JG; van Etten J; Patterson MS; Slagboom T; Kiemeneij F; Laarman GJ
    JACC Cardiovasc Interv; 2011 Jan; 4(1):24-9. PubMed ID: 21251625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Kounis syndrome in everolimus-eluting stents and paclitaxel-eluting stents.
    Kounis NG; Giannopoulos S; Goudevenos JA
    Catheter Cardiovasc Interv; 2010 Dec; 76(7):1076-7; author reply 1078. PubMed ID: 21086494
    [No Abstract]   [Full Text] [Related]  

  • 13. Why we do what we do? Making sense of antithrombotic therapy in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
    Brener SJ
    JACC Cardiovasc Interv; 2010 Jun; 3(6):678-9. PubMed ID: 20630462
    [No Abstract]   [Full Text] [Related]  

  • 14. The process of bringing new drug-eluting stents to market will they see the light of day?
    Holmes DR; Patel M
    JACC Cardiovasc Interv; 2008 Oct; 1(5):533-4. PubMed ID: 19463355
    [No Abstract]   [Full Text] [Related]  

  • 15. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty).
    Spaulding C; Teiger E; Commeau P; Varenne O; Bramucci E; Slama M; Beatt K; Tirouvanziam A; Polonski L; Stella PR; Clugston R; Fajadet J; de Boisgelin X; Bode C; Carrié D; Erglis A; Merkely B; Hosten S; Cebrian A; Wang P; Stoll HP; Henry P
    JACC Cardiovasc Interv; 2011 Jan; 4(1):14-23. PubMed ID: 21251624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incomplete stent apposition: should we appose or oppose?
    Lindsey JB; Marso SP
    JACC Cardiovasc Interv; 2010 May; 3(5):495-7. PubMed ID: 20488405
    [No Abstract]   [Full Text] [Related]  

  • 18. Bifurcation stenting: a commitment to always kiss.
    Hillegass WB
    Catheter Cardiovasc Interv; 2010 Mar; 75(4):614-5. PubMed ID: 20333659
    [No Abstract]   [Full Text] [Related]  

  • 19. Angiographic restenosis and clinical recurrence after sirolimus- and paclitaxel-eluting stent implantation.
    Vlaar PJ; Zijlstra F
    JACC Cardiovasc Interv; 2009 Aug; 2(8):776-8. PubMed ID: 19695547
    [No Abstract]   [Full Text] [Related]  

  • 20. Sirolimus- versus paclitaxel-eluting stents for unselected patients with coronary artery disease.
    Park SJ
    Catheter Cardiovasc Interv; 2011 Jan; 77(1):13-4. PubMed ID: 21181967
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.